{"artifact":{"id":"rp-ad-trem2-202604280307","artifact_type":"research_plan","entity_ids":"[\"TREM2\", \"Alzheimer's disease\"]","title":"AD Research Plan: TREM2 targeting in Alzheimer's disease","quality_score":0.88,"created_by":"ad_master_plan_synthesizer","provenance_chain":"[]","content_hash":"0794e57d127a53c29f3942b52f85d52f452ba898241a5bd548843bc5358c5f7f","metadata":{"_origin":{"url":null,"type":"internal","tracked_at":"2026-04-28T03:07:53.650663"},"disease":"Alzheimer's disease","cost_usd":986500.0,"timeline":"18-24 months","prereg_id":"6","assay_spec":"Phase 2 RCT comparing TREM2 modulator vs. placebo in N=300 early AD patients, primary endpoint: change from baseline on composite cognitive score at 18 months. Sample size powered at 80% for effect size=0.45, alpha=0.05.","hypothesis":"TREM2 enhancement reduces microglial dysfunction and downstream tau pathology, slowing AD progression","power_calc":{"test":"two-sided t-test","alpha":0.05,"power":0.8,"effect_size":0.45},"sample_size":300,"target_gene":"TREM2","kill_criteria":["TREM2 loss-of-function variants show no AD risk modulation in replication cohort (OR=1.0, p>0.05)","Microglial TREM2 knockout in 5xFAD mice fails to alter amyloid plaque burden","TREM2 agonist fails to reduce tau pathology in P301S tauopathy model"],"_schema_version":1,"primary_endpoint":"Composite cognitive score (ADAS-Cog13 + ADCS-ADL)","upstream_target_id":"ut-ad-trem2-202604280307","identification_strategy":"MR + KO"},"created_at":"2026-04-27T20:07:53.650758-07:00","updated_at":"2026-04-27T20:07:53.650758-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":null,"citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"e577e943-30e4-4290-977f-61d967821516","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"ad_master_plan_synthesizer"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[{"target_artifact_id":"ut-ad-trem2-202604280307","link_type":"derives_from","strength":1.0,"evidence":"Research plan tests upstream target ut-ad-trem2-202604280307"}],"incoming_links":[],"current_artifact_id":"rp-ad-trem2-202604280307","is_canonical":true,"supersede_chain":["rp-ad-trem2-202604280307"]}